Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sequential therapy with dacarbazine and carmustine: a phase I study

R B Mitchell1, M E Dolan, L Janisch

  • 1Department of Medicine, University of Chicago, Illinois 60637.

Cancer Chemotherapy and Pharmacology
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.

Clinical pharmacology and therapeutics·2017
Same author

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.

Clinical pharmacology and therapeutics·2017
Same author

Food Effect Studies for Oncology Drug Products.

Clinical pharmacology and therapeutics·2017
Same author

Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program.

Clinical pharmacology and therapeutics·2016
Same author

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.

The pharmacogenomics journal·2016
Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026
Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026
Same journal

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Severe Methotrexate toxicity after ectopic pregnancy: a case report managed with continuous renal replacement therapy.

Cancer chemotherapy and pharmacology·2026
Same journal

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026
See all related articles

Dacarbazine (DTIC) combined with carmustine (BCNU) aims to deplete DNA-repair protein AGT in cancer patients. Recommended Phase II doses are 1,000 mg/m2 DTIC and 75 mg/m2 BCNU, though complete AGT depletion was not achieved.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • O6-alkylguanine-DNA alkyltransferase (AGT) depletion enhances sensitivity to chloroethylnitrosoureas like carmustine (BCNU).
  • Dacarbazine (DTIC) has demonstrated potential in depleting AGT activity in preclinical models.

Purpose of the Study:

  • To determine the DTIC dose for maximal AGT depletion in patient PBMCs.
  • To establish the maximally tolerated dose of DTIC when infused before BCNU.

Main Methods:

  • A Phase I trial involving 42 patients with refractory solid tumors.
  • DTIC was administered as a 4-hour infusion, followed by a 2-hour BCNU infusion.
  • AGT activity in peripheral blood mononuclear cells (PBMCs) was measured at various time points.

Related Experiment Videos

Main Results:

  • Complete AGT depletion was not achieved even at DTIC doses up to 750 mg/m2.
  • Recommended Phase II doses are 1,000 mg/m2 DTIC followed by 75 mg/m2 BCNU.
  • AGT activity decreased to approximately 62-65% of baseline by 4-24 hours post-DTIC initiation; no dose-response correlation was observed.

Conclusions:

  • The combination of DTIC and BCNU shows potential for AGT modulation in cancer patients.
  • Hematologic toxicity was dose-limiting, with non-hematologic toxicity observed at higher BCNU doses.
  • Further investigation is warranted to optimize DTIC and BCNU dosing for maximal therapeutic benefit and minimal toxicity.